AngioDynamics (NASDAQ:ANGO) Upgraded at Zacks Research

Zacks Research upgraded shares of AngioDynamics (NASDAQ:ANGO) from a strong sell rating to a hold rating in a research note issued to investors on Monday,Zacks reports.

Several other equities analysts have also recently issued reports on the stock. HC Wainwright boosted their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Canaccord Genuity Group raised their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

AngioDynamics Stock Down 1.6%

NASDAQ:ANGO opened at $14.19 on Monday. The firm’s fifty day simple moving average is $15.46 and its 200 day simple moving average is $13.11. The stock has a market cap of $596.69 million, a P/E ratio of -16.31 and a beta of 0.30. AngioDynamics has a twelve month low of $9.39 and a twelve month high of $16.29.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts expect that AngioDynamics will post -0.25 EPS for the current fiscal year.

Insider Activity

In related news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in AngioDynamics during the second quarter valued at $49,480,000. Weber Capital Management LLC ADV purchased a new stake in shares of AngioDynamics in the second quarter worth $17,649,392. Paradigm Capital Management Inc. NY bought a new position in shares of AngioDynamics during the second quarter valued at $8,732,000. Western Standard LLC bought a new position in shares of AngioDynamics during the second quarter valued at $5,037,000. Finally, Bank of America Corp DE raised its position in shares of AngioDynamics by 262.7% in the 1st quarter. Bank of America Corp DE now owns 503,640 shares of the medical instruments supplier’s stock worth $5,726,000 after purchasing an additional 364,763 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.